ERBB2 and neoplasm: Subsequent research, however, has revealed significant levels of tumor-infiltrating lymphocytes (TILs) within more aggressive BCA subtypes, such as TNBC and Her-2 positive, correlating with enhanced 5-year overall survival (OS; 74.3% in patients with high TILs vs. 52.0% in those with low TILs), pathologic complete response (pCR; 40–50% in the high TIL group), and disease-free survival (DFS) [78,79,80].